ValGenesis Horizon is an established enterprise VLMS for pharma and biotech. Like its peers, it is bought through demos and quotes and deployed as a project. This guide covers what a ValGenesis alternative needs to deliver, and where Valiqa fits for teams that want full generation and the Part 11 lifecycle without the enterprise rollout.
Valiqa is the self-serve alternative to ValGenesis Horizon. It generates complete validation protocol content, test steps and acceptance criteria included, directly from your equipment specifications, where ValGenesis assembles a draft from existing templates. Valiqa also runs the full Part 11 lifecycle itself: e-signatures with configurable approval routing, a hash-chained audit trail, deviation management with CAPA linkage, and guided step-by-step execution with per-step witnessed signatures. Pricing is public from $199/mo with an instant free trial. Where ValGenesis keeps its edge is multi-site execution coordination and established large-enterprise deployments in pharma and biotech.
Buying means a demo, a proposal, and an implementation timeline measured in weeks to months, with pricing available only through sales.
Generation is template-driven: the Smart Validation Document Generator adapts existing validation templates into a draft, which means generation depends on the validation templates you already have rather than being generated from scratch.
The platform is scoped to large pharma and biotech enterprises. Mid-market teams and device-first companies often need broader standards coverage and a lighter footprint.
Some teams want to start from the equipment, not from documentation: give the system a make, model, and parameters and get a protocol, rather than curating templates first.
The full VLMS footprint is more platform than a single-site validation program needs, while the essentials, generation, e-signatures, audit trail, deviations, and execution, are what actually gets used.
Ask whether the system generates complete protocol content from equipment specifications, or adapts existing templates into a draft. The difference decides how much authoring work stays with your team.
Reviewer, approver, and releaser roles with configurable signature policies, so the approval workflow matches your SOPs rather than the other way around.
Tamper-evident, exportable, and covering protocols and deviations alike.
Step-by-step in-app execution with per-step witnessed Part 11 signatures, enforced sequencing, execution locking, and a signed close-out. Verify this explicitly; it is the core of what a VLMS does.
Failing results should route into deviations with impact assessment, link to corrective and preventive actions, and close under e-signature.
ValGenesis is built around pharma and life sciences. If you also run medical devices, biotech, or food safety lines, the alternative should cover those frameworks. Valiqa covers 20+ standards across all four.
A public price and an instant trial mean you can validate the output against your own equipment before any commitment.
| Dimension | Valiqa | ValGenesis |
|---|---|---|
How you buy | Self-serve, public $199+/mo, instant free trial | Book a demo, quote-only |
Time to first protocol | Minutes | Weeks to months |
Generates protocol content | ✓ | ◐ |
Input model | Equipment specs (make/model/params) | Requirements/lifecycle |
Part 11 lifecycle (e-sig, audit trail, deviations, CAPA) | ✓ | ✓ |
Guided electronic execution (run protocols step-by-step in-app) Valiqa runs digital execution step-by-step in-app: per-step result, evidence, and real-time deviation on a failing step; per-step Part 11 e-signatures (performer plus an independent witness, separation of duties); enforced step sequencing, execution locking, and operator assignment; a signed executed close-out; plus a controlled paper-execution path with independent second-person verification (ALCOA+). Enterprise multi-site coordination remains the VLMS platforms' edge | ✓ | ✓ |
Scope | AI-native validation platform (generation + Part 11 lifecycle) | Full validation lifecycle suite |
Target company size | Mid-market (10-500) | Enterprise / large |
Standards coverage | 20+ across med device, pharma, biotech, food | Pharma / life sciences |
For the full head-to-head breakdown, read Valiqa vs ValGenesis.
Multi-site execution coordination and established large-enterprise deployments. (Valiqa now covers guided step-by-step execution itself: per-step witnessed Part 11 e-signatures, enforced sequencing, execution locking, operator assignment, and a signed close-out.)
Full enterprise VLMS breadth: multi-site coordination and established large-enterprise deployments across pharma and biotech.
Template reuse across a large existing document library, useful if you already have years of validation documentation to draw from.
Valiqa is not affiliated with ValGenesis. All trademarks belong to their respective owners. Comparison based on publicly available information as of August 2026.
We use essential cookies for authentication and security. With your consent, we also use Microsoft Clarity, Google Analytics, and the LinkedIn Insight Tag on our marketing pages to understand how visitors navigate the site and to measure our advertising. Learn more.